Tumor Immune Evasion Induced by Dysregulation of Erythroid Progenitor Cells Development

• Published in: Cancers 2021-02, Vol.13 (4), p.870
• Main Authors: Grzywa, Tomasz M, Justyniarska, Magdalena, Nowis, Dominika, Golab, Jakub
• Format: Article
• Language: English
• Subjects: Apoptosis; Cancer; Cell differentiation; Cyclin-dependent kinases; Erythrocytes; Erythroid cells; Erythropoiesis; Fibroblasts; Growth factors; Homeostasis; Hypoxia; Immune evasion; Immune response; Immunosuppression; Immunosurveillance; Immunotherapy; Interleukin 10; Kinases; Lymphocytes T; Macrophages; Metastases; PD-L1 protein; Progenitor cells; Reactive oxygen species; Review; Spleen; Stem cells; Suppressor cells; Transforming growth factor-b; Tumor necrosis factor-TNF; Tumors
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers13040870

Cancer cells harness normal cells to facilitate tumor growth and metastasis. Within this complex network of interactions, the establishment and maintenance of immune evasion mechanisms are crucial for cancer progression. The escape from the immune surveillance results from multiple independent mechanisms. Recent studies revealed that besides well-described myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs) or regulatory T-cells (Tregs), erythroid progenitor cells (EPCs) play an important role in the regulation of immune response and tumor progression. EPCs are immature erythroid cells that differentiate into oxygen-transporting red blood cells. They expand in the extramedullary sites, including the spleen, as well as infiltrate tumors. EPCs in cancer produce reactive oxygen species (ROS), transforming growth factor β (TGF-β), interleukin-10 (IL-10) and express programmed death-ligand 1 (PD-L1) and potently suppress T-cells. Thus, EPCs regulate antitumor, antiviral, and antimicrobial immunity, leading to immune suppression. Moreover, EPCs promote tumor growth by the secretion of growth factors, including artemin. The expansion of EPCs in cancer is an effect of the dysregulation of erythropoiesis, leading to the differentiation arrest and enrichment of early-stage EPCs. Therefore, anemia treatment, targeting ineffective erythropoiesis, and the promotion of EPC differentiation are promising strategies to reduce cancer-induced immunosuppression and the tumor-promoting effects of EPCs.